(CMMB) Chemomab Therapeutics DRC - Ratings and Ratios

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibrotic and inflammatory diseases. The companys lead candidate, CM-101, is a humanized monoclonal antibody designed to modulate CCL24, a chemokine implicated in fibrotic and inflammatory pathways. CM-101 is currently in Phase 2 clinical trials for the treatment of primary sclerosing cholangitis (PSC), a chronic liver disease, and systemic sclerosis (SSc), a multi-organ autoimmune disorder. The company leverages its expertise in immunology and fibrosis biology to target pathways with high unmet medical need. Founded in 2011 and headquartered in Tel Aviv, Israel, Chemomab is advancing a pipeline aimed at addressing debilitating fibrotic and inflammatory conditions.

From a technical perspective, CMMBs stock has shown volatility, with an Average True Range (ATR) of 0.16, indicating moderate price fluctuations. The stock is currently trading below its 20-day, 50-day, and 200-day Simple Moving Averages (SMA), which are 1.71, 1.92, and 1.52, respectively. This suggests bearish momentum in the near term. The average 20-day trading volume is 867,630 shares, reflecting moderate liquidity.

On the fundamental side, Chemomab has a market capitalization of $27.91 million, with a forward P/E ratio of 13.00, indicating expectations of future earnings growth. The companys price-to-book (P/B) ratio of 1.95 suggests that the market values the company slightly above its book value. However, the return on equity (RoE) of -88.73% highlights significant operating losses, a common characteristic of early-stage biotechnology companies.